The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost per median month of progression-free survival for daratumumab plus bortezomib and dexamethasone compared with carfilzomib plus dexamethasone in relapsed/refractory multiple myeloma.
 
Eric Maiese
Employment - Janssen Scientific Affairs
Stock and Other Ownership Interests - Johnson & Johnson
 
Christopher N. Graham
Research Funding - Amgen (Inst); Celgene (Inst); CSL Behring (Inst); Janssen Scientific Affairs (Inst); Lilly (Inst); Regeneron (Inst); Sanofi/Aventis (Inst)
 
Emma Hawe
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Janssen Scientific Affairs (Inst); Lilly (Inst); Lilly (Inst); Novartis (Inst); Novartis (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); UCB (Inst); UCB (Inst)
 
Jean-Gabriel Le Moine
Research Funding - Biogen (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen Scientific Affairs (Inst); Lilly (Inst); Novartis (Inst); Shionogi (Inst)